MedTrace Logo

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

NCT03452345 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-07-28

No results posted yet for this study

Summary

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

Conditions

  • Masseter Muscle Hypertrophy

Interventions

DRUG

Meditoxin

Meditoxin (Botulinum toxin type A)

DRUG

Placebo

Placebo (Normal saline)

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-09
Primary Completion
2019-01-31
Completion
2019-04-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452345 on ClinicalTrials.gov